Interleukin Genetics Names Ramon W. Mohanlal, M.D. as Chief Medical Officer
07/11/2005
INTERLEUKIN GENETICS NAMES RAMON W. MOHANLAL, M.D. AS CHIEF MEDICAL OFFICER
Waltham, MA, July 11, 2005 – Interleukin Genetics, Inc. (OTCBB: ILGN) announced today that it has named Ramon W. Mohanlal, M.D., Ph.D., MBA, a physician with specialist training in internal medicine and cardiology, and with a strong drug development background to the post of Chief Medical Officer.
Just prior to joining Interleukin Genetics, Dr. Mohanlal spent more than three years as a Medical Director at Vertex Pharmaceuticals, Inc, where he was responsible for developing its anti-inflammatory drug portfolio. He has also served as Director of Research at Syncytium, Inc. and worked previously for Pharmacia and GlaxoWellcome in positions of increasing seniority in various clinical development programs.
"I am delighted to have Dr. Mohanlal join our Senior Management team”, said Philip Reilly, MD, JD, CEO of Interleukin Genetics. “With his extensive experience in drug development and deep knowledge of inflammation and pharmacogenetics, he greatly strengthens our ability to undertake efforts to make personalized medicine a reality”.
"I am really excited to be joining Phil Reilly, Ken Kornman,, the Company’s Chief Scientific Officer, and the remainder of the team at Interleukin Genetics”, says Dr. Mohanlal. "Interleukin Genetics has the technology, clinical data, and commercial partnerships to be a leader in the field of personalized health care. The company's relationships with many leading academic researchers have led to a number of important discoveries and developments involving the role of the Interleukin-1 genes in influencing risk for diseases. Its strategic alliance with Alticor, Inc. represents an extraordinary opportunity to translate emerging knowledge about nutritional genetics into valuable products to enhance healthy life styles. I am looking forward to contributing to Interleukin’s therapeutic initiatives and to the development of highly focused nutritional products. The products in development are designed to avert or alter the trajectory of the many common disorders that are influenced by variations in individuals’ genes. I am especially hopeful about the possibilities in cardiovascular disease, metabolic disorders, and osteoporosis”.
About Interleukin
Interleukin Genetics is a biotechnology company focused on developing personalized health products. The company uses functional genomics to help in the development of risk assessment tests, pharmacogenetic tests, nutritional and therapeutic products based on the genetic variations in people. Interleukin's current programs focus on cardiovascular disease, osteoporosis, periodontal disease and weight management. Interleukin expects that these programs will lead to products that will personalize the selection of nutritional and therapeutic products and enable consumers to manage their health care. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in our annual report on Form 10-K, our Form 10-K/A, our quarterly reports on Form 10-Q and in other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
For Interleukin Genetics:
Fenel M. Eloi
Chief Operations Officer, CFO
Interleukin Genetics, Inc.
(781) 398-0700